- Global Pharma News & Resources

Boehringer Ingelheim and inmation Software enhance collaboration

Boehringer Ingelheim and inmation Software enhance collaboration

Boehringer Ingelheim, one of the world’s leading research-driven pharmaceutical companies, and inmation Software GmbH, a technology leader in global real-time information management for large-scale industries, today announce the strategic expansion of their collaboration. Specifically, this revolves around a joint development agreement, initially for the next five years, for the further development of the “enterprise:inmation” software.


The enterprise:inmation system is a software solution which enables process and production data to be acquired on a global basis in real-time, involving systems and components independent of manufacturer, and make it available model-based. Its core element is a concept which can be rolled out globally but is at the same time minimally invasive and highly scalable, simply using existing systems. This enables the integration of all systems with a digital interface such as ERP, MES, PIMS, SCADA, LIMS, DCS or PLC into a global real-time data backbone. As a result the data from heterogeneous systems is pulled into a homogeneous database that enables users to access the relevant information required at the appropriate level of detail web-based from anywhere with any device.


The joint development agreement between the two companies envisages close collaboration between the Cologne-based software developers and the Factory Automation Team at Boehringer Ingelheim and has a clearly defined road map. Apart from data acquisition and data integration the joint development also focuses on data analysis. It is an essential step towards a smart factory and is the basis for applications such as batch analysis or predictive maintenance in an environment of validation and regulation by pharmaceutical authorities.


“Our experience since we entered our global license agreement with enterprise:inmation in 2017 has been very good – both with the software and in terms of our working relationship with inmation,” reports Mary Mercado, Vice President IT Operations at Boehringer Ingelheim. “A deepening of our partnership with inmation is the next logical step for us in driving forward our goals with regard to the digitalization of our factories. enterprise:inmation is already in a position to meet many regulatory challenges in the pharmaceutical field, but we also see enormous potential in further development as well. For us the aim of the agreement which has been concluded is to ensure that there is a focus on our requirements in the further development of the software.”


“For inmation the recently concluded contract with Boehringer Ingelheim is a huge endorsement of our work. For our partner with its facilities worldwide enterprise:inmation provides the backbone for global data acquisition and analysis in real-time and therefore the basis for end-to-end digitalization, data integrity and paperless documentation,” says Timo Klingenmeier, CEO of inmation Software GmbH. “We are delighted that Boehringer Ingelheim has decided to take our work together, so far on a project basis and in our Product Advisory Board, up to yet another level and open up new opportunities for us in the further development of our software.”

Editor Details

Last Updated: 18-Nov-2020